Functional Brands Announces Third Quarter 2025 Financial Results
Lake Oswego, Oregon--(Newsfile Corp. - December 15, 2025) - Functional Brands Inc. (NASDAQ: MEHA), a leading innovator in wellness and performance products, today announced financial results for the third quarter ended September 30, 2025. Third Quarter 2025 highlights: Revenue of $1.7 million increased 21.4% compared to the third quarter of 2024, primarily due to growth in direct-to-consumer sales Gross profit increased 28.1% com
Household / Consumer / Cosmetics, Health
2025-12-15 4:05 PM EST | Functional Brands Inc.
Edison Issues Report on VinFast Auto (VFS)
London, United Kingdom--(Newsfile Corp. - December 15, 2025) - Edison issues report on VinFast Auto (NASDAQ: VFS). VinFast Auto (VFS) is a Vietnamese pure-play electric vehicle (EV) manufacturer that has transitioned from internal combustion engines to a fully electric line up of EV passenger cars, e-scooters and e-buses. The company is leveraging its core competencies in Vietnam (one of the fastest-growing EV markets globally) and its integrated EV ecosystem to expand in India, Indones
Banking / Financial Services, Computer Hardware, Computer Software, Health
2025-12-15 10:38 AM EST | Edison Group
Adia Nutrition Inc. Announces IRB Approval from BeyondBound for Adia Med's Autism Clinical Study
Winter Park, Florida--(Newsfile Corp. - December 15, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine through its Adia Med subsidiary, today announced that the independent Institutional Review Board (IRB) BeyondBound has approved the company's patent-pending clinical study protocol focused on Autism Spectrum Disorder (ASD).
Healthcare and Hospitals, Health
2025-12-15 10:30 AM EST | Adia Nutrition Inc.
Apyron Pioneering Next Generation Pain Management Solutions
Atlanta, Georgia--(Newsfile Corp. - December 15, 2025) - Apyron, Inc. is a medical technology company with a product portfolio designed to address chronic pain and joint-related disorders, with a core value to restore mobility in patients and provide them agency over their therapy. Apyron's product portfolio is being developed to address two major contributors to disability — chronic lower back pain and joint disease. Chronic pain markets account for over $384 million of healthcare spe
Biotechnology, Healthcare and Hospitals, Health
2025-12-15 9:00 AM EST | Apyron, Inc.
CBIH: Potential Rescheduling to Schedule III Could Reward Decades of Scientific Preparation and Regulatory Discipline
Houston, Texas--(Newsfile Corp. - December 15, 2025) - Dante Picazo, CEO of Cannabis Bioscience International Holdings, Inc. trading under ticker symbol CBIH (OTCID: CBIH), provided the following update in light of recent reports suggesting that President Donald Trump may issue an executive order aimed at accelerating the federal process of rescheduling cannabis from Schedule I to Schedule III. CBIH believes that, if the process moves forward, it could represent one of the most conseque
Biotechnology, Pharmaceuticals, Cannabis, Health
2025-12-15 7:00 AM EST | Cannabis Bioscience International Holdings
Edison Issues Report on discoverIE Group (DSCV)
London, United Kingdom--(Newsfile Corp. - December 15, 2025) - Edison issues report on discoverIE Group (LSE: DSCV). discoverIE reported solid H126 results, with adjusted EPS growth of 6% on reported revenue growth of 2.5%. Organic revenue growth has resumed at the group level and in three out of the four operating units, and two acquisitions have just been announced. Having managed the group to grow earnings and optimise cash during an 18-month period of organic revenue reduction due t
Banking / Financial Services, Computer Hardware, Computer Software, Health
2025-12-15 6:06 AM EST | Edison Group
NervGen Pharma Announces Proposed Amendment to Warrants
Vancouver, British Columbia--(Newsfile Corp. - December 12, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other traumatic and neurologic disorders, today announced that the Company intends to amend 5,075,000 common share purchase warrants (the "2022 Warrants") that were issued pursuant to a private placement of units that c
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-12-12 7:51 PM EST | NervGen Pharma Corp.
MyndTec Inc. Completes Ninth Tranche of Non-Brokered Private Placement
Mississauga, Ontario--(Newsfile Corp. - December 12, 2025) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the "Company"), a neurological treatment and rehabilitation medical technology company, is pleased to announce that it has closed the ninth tranche of its non-brokered private placement previously announced on January 30, 2025 (the "Offering"). The ninth tranche of the private placement consists of 553,926 Units of the Company (the "Units") at a price of $0.20 p
Technology, Healthcare and Hospitals, Health
2025-12-12 5:39 PM EST | MyndTec Inc.
Davos 2026 Marks a Milestone for Longevity and Frontier Investments
Davos, Switzerland--(Newsfile Corp. - December 12, 2025) - Longevity Investors announces two influential private gatherings taking place during World Economic Forum (WEF) week in January 2026: the Longevity Investors Lunch (LIL) on 20 January, and the inaugural Future Investments Circle (FIC) on 22 January, a new initiative of Future Investments, co-hosted by Longevity Investors and Global Conversations, the renowned Davos event curator.
2025-12-12 3:19 AM EST | Longevity Investors AG
Edison Issues Report on Borussia Dortmund (BVB)
London, United Kingdom--(Newsfile Corp. - December 12, 2025) - Edison issues report on Borussia Dortmund (FSE: BVB) Borussia Dortmund is one of Europe's leading football clubs, with a strong track record in its domestic league and an enviable consistency in competing in the financially lucrative European competitions. The consistent on-pitch success and structural growth drivers of expanding global audiences, increasing demand for media rights and developing sponsorship partners have le
Banking / Financial Services, Computer Hardware, Computer Software, Health
2025-12-12 2:44 AM EST | Edison Group
Hemostemix CEO Introduces Conformal Consciousness Hypothesis A = E/(hv)
Calgary, Alberta--(Newsfile Corp. - December 11, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from vascular dementia, angina, ischemic cardiomyopathy, congestive heart failure, non-ischemic dilated cardiomyopathy, pain, total body ischemia, peripheral arterial disease and chronic limb threatening ischemia, is pleased to announce that Thomas Smeenk
Biotechnology, Pharmaceuticals, Health
2025-12-11 9:40 AM EST | Hemostemix Inc.
HPN Holdings, Inc. Executes Letter of Intent to Merge with Innovative Nonstandard Auto Insurance Provider Orange Insurance
Chicago, Illinois--(Newsfile Corp. - December 11, 2025) - In a move signaling the future of nonstandard auto insurance, HPN Holdings, Inc. (OTCID: KICK) has executed a Letter of Intent to merge with Orange Auto Insurance. The combined company will trade on the OTCIQ Market under the ticker symbol KICK. Orange Auto Insurance brings a seasoned management team as well as next generation AI technology which provides a significant competitive advantage over current legacy auto insurance pro
2025-12-11 9:27 AM EST | HPN Holdings, Inc.
Hemostemix Grants Stock Options
Calgary, Alberta--(Newsfile Corp. - December 11, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that in accordance with its stock option plan, it has granted on December 11, 2025, subject to regulatory approval, a total of 963,000 stock options to purchase common shares of Hemostemix (the "Options") to directors, officers, employees and consultants of Hemostemix. Of the Options granted, 663,000 vest immediately and
Biotechnology, Pharmaceuticals, Health
2025-12-11 8:57 AM EST | Hemostemix Inc.
BetterLife Pharma Announces Engagement with Shanghai-Based YAFO Capital
Vancouver, British Columbia--(Newsfile Corp. - December 11, 2025) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biotech company focused on development of BETR-001, its proprietary non-hallucinogenic derivative of lysergic acid diethylamide ("LSD"), is pleased to announce it has signed an engagement agreement with Shanghai-based YAFO Capital ("YAFO"), as its exclusive advisor to seek strategic partnerships for develo
2025-12-11 8:00 AM EST | BetterLife Pharma Inc.
Safe Supply Announces Closing of Upsized Financing
Toronto, Ontario--(Newsfile Corp. - December 11, 2025) - Safe Supply Streaming Co Ltd. (CSE: SPLY) (OTCQB: SSPLF) (FSE: QM4) ("Safe Supply" or the "Company"), a pioneer in health, safety and rapid response technologies, is pleased to announce that, further to its news releases dated November 24, 2025 and December 9, 2025, it has closed its upsized non-brokered private placement (the "Offering") for total gross proceeds of $935,000. The Offering was upsized from an initial
2025-12-11 7:00 AM EST | Safe Supply Streaming Co Ltd.
Quantum BioPharma Announces Closing of Private Placement & Provides Corporate Update
Toronto, Ontario--(Newsfile Corp. - December 10, 2025) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, is pleased to announce that, further to its news release o
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-12-10 8:00 PM EST | Quantum BioPharma Ltd.
TempraMed Appoints Leading Diabetes Researcher Professor Dr. Lutz Heinemann to its Scientific Advisory Board
Vancouver, British Columbia--(Newsfile Corp. - December 10, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company"), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, today announced the appointment of Professor Dr. Lutz Heinemann, one of the world's foremost diabetes researchers, to its Scientific Advisory Board. His appointment further enhances TempraMed's scientific foundation as the Company
Technology, Biotechnology, Pharmaceuticals, Health
2025-12-10 5:00 PM EST | TempraMed Technologies Ltd
Defence Therapeutics Announces AGM Results and Provides Corporate Updates
Montreal, Quebec--(Newsfile Corp. - December 10, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a biotechnology company advancing a proprietary intracellular delivery platform that enables more potent, safer, and more effective antibody-based and radiotherapeutic treatments, is pleased to announce that the Shareholders approved all matters presented at the Company's annual general meeting of the shareholders held today, as follows:
Biotechnology, Pharmaceuticals, Health
2025-12-10 4:30 PM EST | Defence Therapeutics Inc.
AAMI Foundation Launches Michael Scholla Packaging Engineering Scholarship Fund
Arlington, Virginia--(Newsfile Corp. - December 10, 2025) - The AAMI Foundation is pleased to announce the launch of the Michael Scholla Packaging Engineering Scholarship Fund, a new philanthropic initiative created to support students pursuing packaging engineering. The Foundation invites individuals, companies, and partners across the packaging and life science
2025-12-10 1:00 PM EST | Association for the Advancement of Medical Instrumentation
Hemostemix Inc. Announces FDA Pre-IND Meeting and NBPP of $960,000
Calgary, Alberta--(Newsfile Corp. - December 10, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from vascular dementia, angina, ischemic cardiomyopathy, congestive heart failure, non-ischemic dilated cardiomyopathy, pain, total body ischemia, peripheral arterial disease and chronic limb threatening ischemia, with ACP
Biotechnology, Pharmaceuticals, Health
2025-12-10 11:17 AM EST | Hemostemix Inc.